(PDF) Safety and Efficacy of Ofatumumab, a Fully Human

Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-Cd20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study

Blood - United States

doi 10.1182/blood-2007-09-111781

Full Text

Open PDF

Abstract

Available in full text

Date

February 1, 2008

Authors

Marinus H. J. van Oers

Publisher

American Society of Hematology

Related search

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology

English

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Hematological Oncology

English

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

American Journal of Hematology

Hematology

2019

English

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

Haematologica

Hematology

2015

English

570 Safety and Efficacy of Bertilimumab, a Human Anti-Eotaxin-1 Monoclonal Antibody, in Bullous Pemphigoid in a Phase 2a Study

Journal of Investigative Dermatology

English

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Medical Council

2017

English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

English

A Phase 1/2 Study of Mt-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of Mt-3724 for the Treatment of Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Hematological Oncology

English

Anti-Ccr4 Monoclonal Antibody KW-0761 (Mogamulizumab) or Investigator's Choice in Subjects With Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATL)

English

Amanote Research

Safety and Efficacy of Ofatumumab, a Fully Human Monoclonal Anti-Cd20 Antibody, in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: A Phase 1-2 Study

Blood - United States

doi 10.1182/blood-2007-09-111781

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Bianca: A Phase 2 Study of the Safety and Efficacy of Tisagenlecleucel in Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study

570 Safety and Efficacy of Bertilimumab, a Human Anti-Eotaxin-1 Monoclonal Antibody, in Bullous Pemphigoid in a Phase 2a Study

Experience With Ibrutinib in Patients With Refractory and Recurrent B-Cell Chronic Lymphocytic Leukemia

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase 1/2 Study of Mt-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of Mt-3724 for the Treatment of Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Anti-Ccr4 Monoclonal Antibody KW-0761 (Mogamulizumab) or Investigator's Choice in Subjects With Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATL)